PTGS2 and cancer: While traditional theories link their effects primarily to the inhibition of cyclooxygenase-2 (COX-2) and reduced prostaglandin production [68], emerging research highlights COX-independent mechanisms, where NSAIDs interact with various proteins, enhancing their anticancer activities [65,69] and helping prevent deep vein thrombosis (DVT) in cancer patients [70].